Studying what predicts severe pain in people with sickle cell disease
Studies factors that may predict severe, lasting pain in people with sickle cell disease.
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Registry title
- Predictors of Pain in Sickle Cell Disease
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 12 Jul 2024
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- Quantitative sensory testing
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 15 to 40 with sickle cell disease who had a pain episode treated with opioids in the past 12 months.
- Age
- 15 to 40 years
- Sex
- All sexes
- Disease stage
- Sickle cell disease (SS, SC or S beta + thalassemia) with at least one pain episode needing opioid treatment at home or in hospital in the 12 months before joining.
- Earlier treatment
- People already taking regular pain medicines (NSAID, acetaminophen) or opioids must have been on a stable dose for 4 weeks before joining.
Main reasons for not taking part
- Pregnant women
- Current or active infection
- Severe pain crisis in the past two weeks that led to an emergency visit or hospital stay
- Stroke with ongoing physical problems that prevent taking part in study procedures
- Not able to understand or complete the study procedures
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosis of sickle cell disease (documentation of SS, SC, S beta + thalassemia, S beta + thalassemia) is required
- Participants must have had at least one sickle cell related pain episode that required treatment with opioids at home or in the hospital 12 months prior to recruitment
- Participants who are on chronic analgesics (NSAID, acetaminophen) or opioids should be on a stable dose for 4 weeks prior to recruitment
Who cannot take part
- Participants with history of severe vaso-occlusive pain crisis resulting in either evaluation in an emergency department or admission to a hospital two weeks prior to study enrollment
- Participants with history of a stroke with ongoing physical impairment that prevents participation in study procedures
- Current or active infection
- Any condition that the principle investigator considers would preclude or bias participation in the study, such as (1) neuropathy from diabetes or other causes, (2) active avascular necrosis requiring treatment for pain
- Age less than 15 or greater than 40 years
- Participants lacking the cognitive or mental capacity to assent to and complete study procedures
- Pregnant females
Other criteria
- All participants must be between 15 and 40 years old and must be able to provide informed, written consent (for adults) or parental consent (for participants younger than 18 years)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 40 years old?
Where in United States
- Duke University Medical CenterDurham, United StatesContact: Martha Kenney, MDTaking people
About the trial
What the trial wants to find out
Sickle cell disease is a painful inherited disorder that affects approximately 100,000 people in the United States, and more than half of these individuals develop chronic or persistent pain that is often severe and disabling. The factors that predict whether an individual with sickle cell disease will develop severe, disabling pain are unclear. The goal of this project is to identify the factors that predict severe pain outcomes in individuals living with sickle cell disease in order to improve pain management strategies and guide future studies of non-opioid therapies for treatment of their pain.
Read full original descriptionShow less
Participants who agree to enroll in this study will be asked to participate in a virtual and then an in-person study visit for their full initial study assessment. They will answer survey questions during the virtual visit, and will be asked to complete several types of standard testing to understand how their body handles pain during the in-person visit. After completing the virtual and in-person sessions, participants will receive text or electronic medical record messages with brief survey (will take less than 8 minutes to complete) on their pain experiences every three months until the study is completed (or up to 48 months for people who are enrolled at the beginning of the study).
The group in the trial
- Individuals living with sickle cell diseaseOther group
Participants living with sickle cell disease will undergo standardized testing called quantitative sensory testing. Quantitative sensory testing measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
Treatment: Quantitative sensory testing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Predictors of Pain Severity and Pain-Related Outcomes in Individuals With Sickle Cell Disease
- Plain-language title
- Studying what predicts severe pain in people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06139510, who can take part
- Record updated
- 5 May 2026